Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: Development and validation of a methylated marker for early diagnosis of prostate cancer

Translational Oncology

Volumn 2, Issue 3, 2009, Pages 146-156

  Ahmed, Hafiz ^a   Cappello, Francesco ^b   Rodolico, Vito ^b   Vasta, Gerardo R ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GALAPTIN; GALECTIN 3; GLUTATHIONE TRANSFERASE P1;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL STRAIN DU 145; CELL STRAIN PC 3; CORRELATION ANALYSIS; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; METHYLATION; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; VALIDATION STUDY;

EID: 77951939167     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09118     Document Type: Article

References (48)

1. Jain S, Chakraborty G, Bulbule A, Kaur R, and Kundu GC (2007). Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 11, 81-90. (Pubitemid 46099754)
2. Nakahara S and Raz A (2008). Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 8, 22-36.
3. Ramsay AG, Marshall JF, and Hart IR (2007). Integrin trafficking and its role in cancer metastasis. Cancer Metastasis Rev 26, 567-578. (Pubitemid 350115108)
4. Nakahara S and Raz A (2007). Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 26, 605-610. (Pubitemid 350115124)
5. Rabinovich GA, Liu FT, Hirashima M, and Anderson A (2007). An emerging role for galectins in tuning the immune response: lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 66, 143-158. (Pubitemid 47063211)
6. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, and Rabinovich GA (2007). Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 64, 1679-1700. (Pubitemid 47036942)
7. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, and Raz A (1999). The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 59, 6239-6245. (Pubitemid 30035648)
8. van den Brûle F, Califice S, and Castronovo V (2004). Expression of galectins in cancer: a critical review. Glycoconj J 19, 537-542.
9. Xu XC, el-Naggar AK, and Lotan R (1995). Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147, 815-822.
10. Schwarz G Jr, Remmelink M, Decaestecker C, Gielen I, Budel V, Burchert M, Darro F, Danguy A, Gabius HJ, Salmon I, et al. (1999). Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. Am J Clin Pathol 111, 623-631. (Pubitemid 29200949)
11. Choufani G, Nagy N, Saussez S, Marchant H, Bisschop P, Burchert M, Danguy A, Louryan S, Salmon I, Gabius HJ, et al. (1999). The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86, 2353-2363. (Pubitemid 30010378)
12. Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, and Tahara E (1994). Expression of a 31-kDa lactoside-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 56, 474-480. (Pubitemid 24094396)
13. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, and Liu FT (1999). Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81, 519-526. (Pubitemid 29203046)
14. Ellerhorst J, Troncoso P, Xu XC, Lee J, and Lotan R (1999). Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 27, 362-367. (Pubitemid 29526142)
15. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, and Cooper CR (2000). Decreased galectin-3 expression in prostate cancer. Prostate 44, 118-123. (Pubitemid 30419186)
16. Su ZZ, Lin J, Shen R, Fisher PE, Goldstein NI, and Fisher PB (1996). Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1, a member of the galectin gene family. Proc Natl Acad Sci USA 93, 7252-7257. (Pubitemid 26243535)
17. Danguy A, Rorive S, Decaestecker C, Bronckart Y, Kaltner H, Hadari YR, Goren R, Zich Y, Petein M, Salmon I, et al. (2001). Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol 16, 861-868. (Pubitemid 32700398)
18. Ahmed H, Banerjee PB, and Vasta GR (2007). Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 358, 241-246. (Pubitemid 46719109)
19. Hessels D, Verhaegh GW, Schalken JA, and Witjes JA (2004). Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 4, 513-526. (Pubitemid 38915277)
20. Keetch DW, Catalona WJ, and Smith DS (1994). Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151, 1571-1574.
21. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, and Getzenberg RH (2007). EPCA-2: a highly specific serum marker for prostate cancer. Urology 69, 714-720. (Pubitemid 46574950)
22. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
23. Jones PA and Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428.
24. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, and Sukumar S (2004). Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64, 4442-4452. (Pubitemid 38856915)
25. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, et al. (2001). Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7, 2727-2730. (Pubitemid 32911377)
26. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, and Sidransky D (2005). Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23, 6569-6575. (Pubitemid 46190250)
27. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, Mehrotra J, Varde S, Chowdary D, Stallings W, et al. (2008). Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 54, 874-882. (Pubitemid 351671598)
28. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, and Sidransky D (2004). Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 10, 5518-5522. (Pubitemid 39100490)
29. Ahmed H, Du SJ, O'Leary N, and Vasta GR (2004). Biochemical and molecular characterization of galectins from zebrafish (Danio rerio). Notochord-specific expression of a proto type galectin (Drgal1-L2) during early embryogenesis. Glycobiology 14, 219-232.
30. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, De Leval J, and Castronovo V (1998). Prognostic value of bone sialo-protein expression in clinically localized human prostate cancer. J Nat Cancer Inst 90, 1000-1008. (Pubitemid 28340442)
31. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, and Paul CL (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89, 1827-1831.
32. Kadrofske MM, Openo KP, and Wang JL (1998). The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 349, 7-20. (Pubitemid 28368385)
33. Singal R, Wert J, and Bashambu M (2001). Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res 61, 4820-4826. (Pubitemid 32691897)
34. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, and Sidransky D (2004). A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10, 8472-8478. (Pubitemid 40053412)
35. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, et al. (2000). Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 46, 1078-1084. (Pubitemid 30643308)
36. Anker P, Lyautey J, Lederrey C, and Stroun M (2001). Circulating nucleic acids in plasma or serum. Clin Chim Acta 313, 143-146. (Pubitemid 33016704)
37. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, and Miller K (2000). Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 60, 5941-5945. (Pubitemid 30839618)
38. Ziegler A, Zangemeister-Wittke U, and Stahel RA (2002). Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 28, 255-271.
39. Su YH, Wang M, Brenner DE, Ng A, Melkonyan H, Umansky S, Syngal S, and Block TM (2004). Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn 6, 101-107. (Pubitemid 38578985)
40. Feinberg AP and Tycko B (2004). The history of cancer epigenetics. Nat Rev Cancer 4, 143-153.
41. Watanabe M, Takagi A, Matsiuzaki T, Kami D, Toyota M, Hirokawa Y, and Shiraishi T (2006). Knowledge of epigenetic influence for prostate cancer therapy. Curr Cancer Drug Targets 6, 533-551. (Pubitemid 44371973)
42. Li LC and Dahiya R (2007). Epigenetics of prostate cancer. Front Biosci 12, 3377-3397.
43. Cross SH and Bird AP (1995). CpG islands and genes. Curr Opin Genet Dev 5, 309-314.
44. Ehrlich M (2002). DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413.
45. Attwood JT, Yung RL, and Richardson BC (2002). DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 59, 241-257. (Pubitemid 34169512)
46. Diaw L, Woodson K, and Gillespie JW (2007). Prostate cancer epigenetics: a review on gene regulation. Gene Regul Syst Bio 1, 313-325.
47. van den Brûle FA, Waltregny D, Liu FT, and Castronovo V (2000). Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89, 361-367. (Pubitemid 30620290)
48. Califice S, Castronovo V, Bracke M, and van den Brûle F (2004). Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23, 7527-7536. (Pubitemid 39389694)